Reta 30 – Retatrutide Pen

Reta 30 – Retatrutide Pen is a retatrutide-based injectable product intended for eligible customers in selected European markets. Retatrutide is an investigational molecule being studied for its potential role in weight management and metabolic health.

Retatrutide has generated considerable interest in obesity research because it acts on three metabolic hormone receptors: GLP-1, GIP and glucagon. This triple-receptor mechanism distinguishes retatrutide from medicines that primarily target the GLP-1 pathway.

Reta 30 European Availability

Reta 30 is currently available for eligible customers in the following countries:

• Austria
• Belgium
• France
• Germany
• Italy
• Hungary
• Spain
• United Kingdom

We currently do not offer Reta 30 / Retatrutide Pen outside these listed countries. Availability is subject to destination-country regulations, import requirements and product eligibility.

Customers from other European countries should contact our team before placing an order to confirm whether delivery can be supported. We do not recommend placing an order from a country that is not listed above without prior confirmation.

About Retatrutide

Retatrutide is being investigated as a GLP-1/GIP/glucagon receptor agonist. Clinical research has examined its potential effects on body weight and metabolic health in adults with overweight or obesity.

Because retatrutide is still under clinical development, research continues to evaluate its safety, efficacy, appropriate dosing and potential long-term use. The EMA has documented retatrutide in connection with an investigation plan for the treatment of obesity.

Why Reta 30 Is Different

The interest surrounding Reta 30 and retatrutide comes from its multi-receptor activity. Rather than acting solely through the GLP-1 pathway, retatrutide is being studied for simultaneous activity at:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

This unique pharmacological profile is one of the reasons retatrutide has become an important subject of ongoing metabolic and obesity research.

European Ordering & Delivery

Reta 30 – Retatrutide Pen is currently offered only for the following destinations:

Austria | Belgium | France | Germany | Italy | Hungary | Spain | United Kingdom

Before ordering, customers should ensure that the product can legally be received in their destination country. Requirements concerning prescription status, importation, customs clearance and possession of investigational medicines may differ between countries.

Orders to countries outside the above list are not currently accepted for Reta 30.

Important Information

Retatrutide is an investigational medicine and is not currently an EU-authorised treatment. Product information should not be interpreted as a claim that retatrutide is approved for the treatment of obesity, weight loss, diabetes or another medical condition.

This page is provided for general product and educational information and does not constitute medical advice. Customers should consult a qualified healthcare professional regarding suitability, potential risks, contraindications, dosing and monitoring.

Availability and delivery are subject to applicable laws and regulations in the destination country.